Eloxx Pharmaceuticals, Inc. (ELOX)
| Market Cap | 121.44M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -34.58M |
| Shares Out | 40.12M |
| EPS (ttm) | -0.86 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $2.54 |
| Previous Close | $2.76 |
| Change ($) | -0.22 |
| Change (%) | -7.97% |
| Day's Open | 2.78 |
| Day's Range | 2.52 - 2.78 |
| Day's Volume | 68,020 |
| 52-Week Range | 1.98 - 6.77 |
Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) has acquired Zikani Therapeutics Inc in an all-stock transaction. The new entity will focus on ribosomal RNA-targeted therapies for the treatment of rare disease...
Combined Company to be Leader in Ribosomal RNA-Targeted Genetic Therapy Bringing Together Complementary Platforms
We expect to report top line data from our Phase 2 cystic fibrosis clinical trials in the first half of this year
Company management to host a webcast and conference call to provide a business update and review financial results at 4:30 p.m. ET Company management to host a webcast and conference call to provide a b...
Publication titled: “ A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX-02 in Healthy Subjects”
Publication titled: “Phase 1 Renal Impairment Trial Results Enable Targeted Individualized Dosing of ELX-02 in Nephropathic Cystinosis Patients” Publication titled: “Phase 1 Renal Impairment Trial Resul...
The CF Foundation's partial funding of the U.S. trial has been extended to partial funding of the global clinical trial program which includes Europe and Israel
Eloxx Pharmaceuticals (ELOX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
WALTHAM, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics ...
Eloxx Pharmaceuticals, Inc. (ELOX) CEO Greg Williams on Q3 2020 Results - Earnings Call Transcript
Expect to report top line data from our Phase 2 cystic fibrosis clinical trials in the first half of 202 1
A Publication titled: “ELX-02: an investigational read-through agent for the treatment of non sen se mutation-related genetic disease” has been published in the Expert Opinion on Investigational Drugs J...
Eloxx Presents Two Preclinical Posters at the 2020 North American Cystic Fibrosis Virtual Conference
WALTHAM, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics ...
Company management to host a webcast and conference call to provide a business update and review financial results at 4:30 p.m. ET Company management to host a webcast and conference call to provide a b...
WALTHAM, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeuti...
WALTHAM, Mass., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutic...
WALTHAM, Mass., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutic...
Eloxx Pharmaceuticals (ELOX) CEO Greg Williams on Q2 2020 Results - Earnings Call Transcript
Enrollment in our Phase 2 clinical trial program for ELX-02 in cystic fibrosis has been resumed in Europe and Israel after being temporarily paused due to the COVID-19 pandemic
ELX-02 had previously been granted orphan medicinal product designation for the treatment of Cystic Fibrosis by the European Medicines Agency ELX-02 had previously been granted orphan medicinal product ...
WALTHAM, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutic...
Company management to host a webcast and conference call to provide a business update and review financial results at 2:00 p.m. ET Company management to host a webcast and conference call to provide a b...
ELX-02 mediates read-through of premature stop codons while maintaining the fidelity of native stop codons ELX-02 mediates read-through of premature stop codons while maintaining the fidelity of native ...
Eloxx Pharmaceuticals (NASDAQ: ELOX) shares are trading higher on Thursday. The company announced that enrollment in its Phase 2 trial for ELX-02 has resumed in Israel and Europe.
WALTHAM, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutic...
It was an overall good week for the market, but the flip to a bearish put-call ratio this morning tells us that there are plenty of volatile stocks poised for short-selling.
Eloxx Pharmaceuticals, Inc. (ELOX) CEO Greg Williams on Q1 2020 Results - Earnings Call Transcript
These five stocks are poised to grow with the guidelines laid out to reopen the economy, as coronavirus pandemic dissipates.
Enrollment in our Phase 2 Cystic Fibrosis Trials has been paused temporarily in response to the COVID-19 pandemic
Eloxx Pharmaceuticals, Inc. (ELOX) CEO Greg Williams on Q4 2019 Results - Earnings Call Transcript
Reiterate topline data from Phase 2 Cystic Fibrosis clinical trials for ELX-02 expected in H1 2020 Results from clinical and preclinical research to date support Company’s prioritization of Cystic F...
Phase 2 cystic fibrosis program for ELX-02 expected to be fully enrolled in the first quarter of 2020 and topline results expected during the first half of 2020
As of late, it has definitely been a great time to be an investor in Eloxx.
As of late, it has definitely been a great time to be an investor in Eloxx Pharmaceuticals, Inc. (ELOX).
Eloxx Preliminary CF Data Should Be Monitored Closely As It Advances Forward
Eloxx Pharmaceuticals, Inc. (ELOX) CEO Robert Ward on Q3 2019 Results - Earnings Call Transcript
Results of our renal impairment study for ELX-02 support the expansion of our research in the kidney beyond nephropathic cystinosis into other areas such as autosomal dominant polycystic kidney disease ...
CF Foundation and Eloxx to form joint program advisory group focused on the development of ELX-02 for cystic fibrosis
WALTHAM, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeuti...
WALTHAM, Mass., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeuti...
WALTHAM, Mass., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutic...
Eloxx Pharmaceuticals, Inc. (ELOX) CEO Robert Ward on Q2 2019 Results - Earnings Call Transcript
As the market played a waiting game, good news lifted several companies higher.
Eloxx Pharmaceuticals (NASDAQ: ELOX) shares spiked higher after the company presented data for its lead investigational drug, ELX-02, at the 42nd European Cystic Fibrosis Society Conference.
Eloxx Pharmaceuticals' (ELOX) CEO Robert Ward on Q1 2019 Results - Earnings Call Transcript
About ELOX
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Waltham, Massachusetts.
| Industry Biotechnology | Founded 2013 |
| CEO Robert Ward | Employees 25 |
| Stock Exchange NASDAQ | Ticker Symbol ELOX |
Analyst Forecasts
According to 3 analysts, the average rating for ELOX stock is "Buy." The 12-month stock price forecast is 4.50, which is an increase of 77.17% from the latest price.